BioMedNewsBreaks

WednesdaySep 16, 2020 2:38 pm

BioMedNewsBreaks – Revive Therapeutics Ltd. (CSE: RV) (OTC: RVVTF) Receives IRB Approval for Bucilliamine COVID-19 Treatment Program

Revive Therapeutics (CSE: RVV) (OTC: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that is has received approval from the independent Institutional Review Board ("IRB") for one of its programs. The program is Revive’s expanded access protocol (“EAP”) for compassionate use of Bucillamine in the treatment of COVID-19. The EAP comprises a multi-center, open-label study of Bucillamine in hospitalized patients suffering from severe COVID-19. The study calls for patients to receive Bucillamine 200 mg orally, three times a day for up to 14 days. Patients will be…

Continue Reading

WednesdaySep 16, 2020 11:37 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Strategic Scientific Advisory Board Appointment

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Eric Milledge has joined DarioHealth as chairman of the company's newly-established Scientific Advisory Board (“SAB”). Milledge has dedicated his entire career to the field of health care, with a focus on pharmaceuticals and medical devices, and spent 34 years at Johnson & Johnson, building a vast network of relationships across the health-care landscape. "We are very pleased that Eric is spearheading our effort to assemble a world-class SAB," said Dario's CEO Erez Raphael in the press release. "He brings significant experience and knowledge relevant to our industry,…

Continue Reading

TuesdaySep 15, 2020 12:43 pm

BioMedNewsBreaks – Why 180 Life Sciences Corp. Is ‘One to Watch’

180 Life Sciences, a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC), with the new entity to be listed under ticker symbol “ATNF” on Nasdaq Capital Market. A recent article discussing the company reads, “180 Life Sciences is leading the research into solving one of the world’s biggest drivers…

Continue Reading

MondaySep 14, 2020 3:19 pm

BioMedNewsBreaks – Seelos Therapeutics Inc. (NASDAQ: SEEL) Secures $7M in Registered Direct Offering

Seelos Therapeutics (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has closed a sale of 8,865,000 shares of common stock with certain institutional investors. According to the update, Seelos Therapeutics secured approximately $7 million in gross proceeds, with each of the shares sold at the price of $0.79. The company also agreed to issue unregistered warrants to the investors to purchase up to 6,648,750 shares of common stock in a concurrent private placement. The warrants have an exercise price of $0.84 per share of common stock, exercisable six months from the date of issuance and with an expiration date five years following…

Continue Reading

MondaySep 14, 2020 12:32 pm

BioMedNewsBreaks – Upcoming Summit to Provide Thought-Provoking Sessions, Interactive Panels for Life Science Professionals

Produced by Lincoln Health Network, the upcoming Strategic HCP/HCO Partnerships Summit is a virtual event that will provide thought-provoking and spotlight sessions and interactive panels. Slated for Nov. 18-20, 2020, the event is specifically designed for life science professionals from pharmaceutical, biotech and medical device organizations. At the 3-day interactive summit, attendees will have the opportunity to enhance their engagement strategy and end-to-end interaction with HCP to drive strategic results while remaining compliant in a digital, physical or hybrid environment. The event already boasts an impressive speaker lineup that organizers continue to update with thought leaders and industry giants. To…

Continue Reading

FridaySep 11, 2020 10:09 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that CEO John Climaco will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference. According to the update, Climaco’s presentation is scheduled to begin at 9:30 a.m. EDT on Wednesday, September 16, 2020, and CNSP management will hold one-on-one virtual investor meetings at the event. Interested parties may register for the presentation by visiting http://ibn.fm/3BGwC . In addition, a replay of the presentation will be available on the company's…

Continue Reading

ThursdaySep 10, 2020 12:09 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Announces Promising Results From Second Preclinical Study of AV-101 – Probenecid Combination

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, recently announced positive new data from the company's second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. According to the update, results of the new study complement previous preclinical data demonstrating the combination's potential to substantially increase the brain concentration of AV-101's active metabolite, 7-Cl-KYN, a potent and selective full antagonist of the NMDA receptor glycine co-agonist site, thereby reducing NMDA receptor signaling. "These new positive results amplify our message that AV-101, when administered in…

Continue Reading

WednesdaySep 09, 2020 11:53 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Secures C$13.29M Through Previously Announced Offering

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today confirmed that it has closed its previously announced offering of units for aggregate gross proceeds of approximately C$13.29 million. According to the update, the company issued 15,640,000 units, each at a price of C$0.85, with each unit consisting of one common share of the company and ½ of one common share purchase warrant, with each whole warrant entitling the holder to purchase one share, at the price of C$1.10 per share, until September 9, 2023. “Over the last four years, LexaGene…

Continue Reading

TuesdaySep 08, 2020 2:22 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, recently announced board appointments to align expertise with the company’s strategic vision. These recently appointed board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring to POAI more than a century of invaluable combined experience and life-science, business-development, marketing and financial expertise. An article discussing this quotes POAI CEO Dr. Carl Schwartz, who stated, “These appointments signify our absolute commitment to aligning our board’s expertise with the company’s strategic vision of developing and commercializing an offering that…

Continue Reading

ThursdaySep 03, 2020 11:12 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Progress Report on Critical Steps for Manufacturing of Leading Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has provided updated information on the manufacturing of its lead drug candidate, Berubicin. The company announced it has reached key milestones in the manufacturing process as it has followed a dual-track, drug-product manufacturing strategy; CNS is working with both U.S.-based Pharmaceutics International Inc. (“Pii”) and Italy-based BSP Pharmaceuticals S.p.A. (“BSP”) in producing Berubicin. “As we prepare to initiate our upcoming Berubicin clinical trials, our execution both on the clinical and manufacturing fronts remain paramount to our…

Continue Reading